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Abstract 
The gut microbiota (GM) is the whole of commensal, symbiotic and pathogenic microorganisms 
living in our intestine. The GM-host interactions contribute to the maturation of the host immune 
system, modulating its systemic response. It is well documented that GM can interact with non-
enteral cells as immune cells, dendritic cells and hepatocytes, producing molecules as short-chain 
fatty acids, indole derivatives, polyamines and secondary bile acid. The receptors for some of these 
molecules are expressed on immune cells, and modulate the differentiation of T effector and 
regulatory cells: this is the reason why dysbiosis is correlated with several autoimmune, metabolic 
and neurodegenerative diseases. 
Due to the close interplay between immune and bone cells, GM has a central role in maintaining 
bone health and influences bone turnover and density. GM can improve bone health also increasing 
calcium absorption and modulating the production of gut serotonin, a molecule that interacts with 
bone cells and has been suggested to act as a bone mass regulator. Thus, GM manipulation by 
consumption of antibiotics, changes in dietary habits and the use of pre- and probiotics may affect 
bone health.  
This review summarizes evidences on the influence of GM on immune system and on bone 
turnover and density and how GM manipulation may influence bone health. 
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Introduction 
The whole of the commensal, symbiotic and pathogenic microorganisms living in our intestine has 
been defined gut microbiota (GM), it is acquired at birth and derives almost entirely from the 
mother, it changes accordingly to environmental factors as diet, diseases and use of drugs. The GM 
comprises about 1200 bacterial species, the main phyla represented are: Bacteroidetes, Firmicutes, 
Actinobacteria, Proteobacteria and Verrucomicrobia [1].Some of the identified species and of the 
common bacterial phyla varies between individuals [2], low microbial diversity have been 
identified as a risk factor for different chronic diseases as intestinal inflammatory diseases, obesity 
and insulin resistance [3,4,5,6]. Arumugam and colleagues suggested that individuals can be 
clustered according to the prevalence of different GM phyla and introduced the concept of 
“enterotypes”; according to this definition humans can be stratified on the basis of their microbial 
patterns dominated by Bacteroides, Prevotella or by Ruminococcus [7]. 
In physiological condition GM relationship with host is complex and comprehends various forms of 
symbiotic relationship as parasitic, commensal and mutualistic, GM helps in food digestion, in 
fighting pathogens and, during the first years of post-natal life, contributes to the maturation of the 
host immune system; during the whole life GM interacts with the host and contributes to the 
modulation of gut and systemic immunity. Immune homeostasis disruption is the causal mechanism 
of several chronic non-communicable human diseases (NCDs) as allergy, asthma, some 
autoimmune, cardiovascular and metabolic diseases, and neurodegenerative disorders. These 
disorders are characterized by a low grade of inflammation. Although inflammation and the 
pathways to disease are multifactorial, the altered gut colonization patterns, associated with 
decreasing microbial diversity, are a central theme and are increasingly implicated in the 
physiologic, immunologic, and metabolic deregulation seen in many NCDs. Altered GM-host 
interaction has been indicated as a possible cause of immune deregulation and increased 
inflammation associated with several NCDs [8]. 
This review summarizes evidences on the influence of GM on immune system and on bone 
turnover and density and how GM manipulation may influence bone health. 
 
GM influences immune system 
The interaction between immune system and GM has a central role in the maturation of immune 
system during the early post-natal period [9] and a role in the modulation of immune system and 
response to self-antigens during the whole life [9, 10], thus it has been suggested that dysbiosis may 
play a role in the development of diseases characterized by immune deregulation such as allergies, 
autoimmune, and inflammatory disorders. 
The role of GM in the development and maturation of host immune system in the early post-natal 
life has been demonstrated in germ free (GF) mice, i.d. animal raised in sterile cages that maintains 
sterile gut. The use of this experimental model have shown that the absence of GM negatively 
influences the formation of lymphoid organs, in particular GF mice have defective formation of the 
spleen and mesenteric lymph nodes, the intestinal Peyer’s patch are smaller and displays a reduced 
number of CD4+T cells and reduced production of IgA [11-16]. Also isolated lymphoid follicle and 
cryptopatches are reduced in GF mice [17, 18]. As regards immune cells different GM phyla where 
associated with the development of different T helper (Th) phenotypes: in animal model of 
rheumatoid arthritis (RA) the disease is reduced in GF mice thanks to a reduction of Th 17 [19], 
arthritic phenotypes is restored when GF animals are colonized with segmented filamentous 
bacteria, which enhances the differentiation and function of Th17 cells. In RA patients a 
relationship between the disease and Prevotellaceae has been suggested, in particular Prevotellae 
copri has been associated with increased risk of RA [20, 21], whereas Prevotella histicola seems to 
inhibit the development of arthritis [22].Colonization of GF animals with Bacterioides fragilis 
restores a correct balance between Th1 and Th2 cells and redirect lymphoid organogenesis [14]. 
Resident bacteria as segmented filamentous bacterium and in particular some Clostridia-related 
species, have been associated to Th cells development and to Tregs cells induction [23, 24]. 
GM modulates immune system through the production of molecules with immunomodulatory and 
anti-inflammatory function that are capable to influence immune cells [25, 26]. In particular GM 
produces several metabolites from digested food, by modifying host products and by the novo 
synthesis, amongst these molecules short-chain fatty acids (SCFAs) are the most widely 
investigated in the regulation of inflammation and immune system. It has been demonstrated that 
SCFAs have anti-inflammatory effects on intestinal mucosa, thus protecting the bowel from the 
development of inflammatory bowel disease [27-29] (Fig. 1). 
SCFAs signals to several non-enteral cell types through G-protein-coupled receptors also named 
free fatty acid receptors (FFAR) [30-32], one of these receptors GPR109A/HCA2, is activated in 
immune system by butyrate [33], the signal between GM and immune system is fundamental to 
regulate the homeostasis and to maintain the balance between immune tolerance to commensals 
bacteria and immunity to pathogens. The interaction of butyrate and GPR109A/HCA2 cooperates in 
the generation of immune tolerance and, in particular, mediates Tregs development [28, 29, 34,35]. 
Butyrate regulates gene expression by inhibiting histone deacetylases (HDAC) [36], in particular  
butyrate inhibits HDAC1 and HDAC3 [37]. Also propionate acts as a less potent HDAC inhibitor 
[38]. Recently it has been suggested that inhibition of HADAC may increase Tregs development 
and function, hence this could be one of the mechanism by which GM enhances Treg generation in 
the gut [39].It has also been suggested that, depending on the cytokines milieu, interaction between 
SCFA and FFAR influences T cells differentiation not only towards Tregs, but also towards effector 
T cells. Park and colleagues suggested that, in certain conditions, SCFAs may induce T helper 
differentiation into Th1 and Th17 thus increasing the host defenses against pathogens [40]. SCFAs 
as butyrate and propionate also modulates antigens presentation inhibiting the development of 
dendritic cells by HDAC inhibition [41-44] and by interaction with FFAR [34, 45]. 
 
Beyond SCFAs, GM produces other metabolites from digested food that have important 
immunomodulatory function as indole derivatives and polyamines, these metabolites derive from 
dietary tryptophan and arginine respectively and have an indirect immune function. Indoles 
derivatives favor the integrity of the enteral mucosa and the barrier defense towards pathogens by 
stimulating the production of anti-microbial peptides, mucins, and proliferation of intestinal goblet 
cells. Polyamines as putrescine, spermidine, and spermine fulfill important roles in gene expression 
and proliferation; enhance the development and maintenance of the intestinal mucosa and resident 
immune cells (Fig. 1). An immunomodulating role have also been postulated for other GM products 
as metabolized bile acids, however physiological role for this metabolites in health and disease is 
still an open question [46]. 
GF mice have imbalance in T helper cells: reduced Treg, absence of Th17 cells and altered ratio 
between Th1 and Th2 with increased Th2 response [26], in these animals gut colonization with 
Bacteroides fragilis induces the development of Th1 cells thanks to the production of 
polysaccharide A [14]. Polysaccharide A is a bacterial product that influences T cells fate thought 
its interaction with the toll like receptor 2, interacting with T cells it favors immune tolerance by 
inhibiting Th17 differentiation and favoring Tregs activity [47]. Other bacteria, as segmented 
filamentous bacteria and Clostridium spp.,were shown to influence Th phenotype, the first 
stimulates Th17 immune response, through ATP or serum amyloid A production by innate 
immunity cells, whereas the latter promotes Treg cell response trough SCFAs production [23, 48] 
(Fig. 1). 
A recent study by Kim and colleagues suggests that GM may affect also B cells antibody 
production through SCFAs inhibition of HDAC and modulation of gene expression [49] however 
further studies are needed to clarify the underling mechanism. 
 
Taken together these evidences suggest that GM influences T cells differentiation through the 
production of bacterial metabolites as SCFAs and polysaccharide A at least at the intestinal mucosa 
level, and T cells differentiation trough cognate bacterial antigens [50] (Fig. 1). 
The majority of the evidences thus suggested that GM metabolites and antigens may influence 
immune regulation and hence dysbiosis may be the environmental factor responsible for some 
immune and inflammatory disorders, both at gut level as inflammatory bowel disease [51] and 
outside the gut as Rheumatoid Arthritis [52], type1 diabetes [53] and asthma [54]. However organs 
distant from gut, skin and lung are not in direct contact with GM, this implies that GM has the 
ability to communicate to the host immune system in distant organs as well as in the gut. These 
signals have been identified in GM derived products as lipopolysaccharide, SCFAs, and bile acid 
but also circulating antibodies or immune cells [2]. 
 
Relationship between GM, immune system activation and bone loss 
Osteoporosis increases dramatically the risk of fractures: major osteoporotic fractures are a social 
and economic burden, in developed countries, the lifetime risk for osteoporotic fractures at the 
wrist, hip or spine is 30% to 40%, very close to that for coronary heart disease. The number of new 
fractures in 2010 in the EU was estimated at 3,5 million, comprising approximately 620,000 hip 
fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 1,800,000 other fractures [55]. 
Osteoporotic fractures impair patients’ quality of life and increase mortality: 20% of elderly patients 
suffering from femoral fractures will die within a year, and 50% of the survivors will lose 
independence. The most frequent cause of bone loss is post-menopausal osteoporosis (PMO) that is 
driven by estrogen deficiency at menopause. In PMO there is an imbalance in bone turnover with 
increased bone resorption and reduced bone formation. It has been demonstrated both in 
experimental models and in humans that estrogen deficiency affects bone cells number and 
activation and bone turnover partially through their effect on immune system [56].During estrogen 
deficiency T cells increase their production of pro-inflammatory and pro-osteoclastogenic 
cytokines, such as TNF alpha and RANKL [57], however the reasons of this increased activity in 
osteoporotic women and not in non-osteoporotic subject is unknown, GM may be involved in the 
mechanism of PMO. 
Some papers suggest that the absence of GM influences bone mass, the majority of the findings 
demonstrate that GF mice have increased bone mass, whereas a single study by Schwarzer and 
colleagues [58] demonstrated that GF mice have a growth retardation due to reduced level of IGF-1 
and, consequently, reduced bone mass. These authors argued that the difference in the results may 
be due to the different genetic background used in the studies. Similarly a study by Yan and 
colleagues reported an effect of GM on IGF-1 and consequently on bone growth, the study 
demonstrated an acute effect of GF colonization with GM obtained from conventional raised mice 
on reduction of bone mass due to increased bone resorption, whereas the long-term colonization 
resulted in a net skeletal growth in young animals [59]. 
Even the studies on mice treated with broad spectrum antibiotics to alter GM bring to different 
conclusions regarding the effect on bone density, these discrepancies are possibly due to differences 
in animal age, sex, and protocols applied for antibiotic treatment [59-63]. 
The majority of the reports suggest that antibiotic treated mice have increased bone density [60, 63, 
64] and also best bone mechanical properties [64] than conventional raised mice. 
GF mice showed a reduced number of osteoclast, lower level of IL-6, RANKL and TNFα in bone, 
these cytokines have a well-known pro-inflammatory and pro-osteoclastogenic effect [65, 66], GF 
mice also displayed alteration of immune system with lower number of CD4+ T cells and no 
difference of CD8+ T cells, these features are normalized by colonization with GM from 
conventionally raised mice [65]. 
Recently elegant studies demonstrated the role of innate immunity in mediating the effect of GM on 
inflammation and on bone metabolism, in particular the role of toll like receptor 5 (TLR5) [64, 66], 
Myd88, Nod1 and Nod2 has been studied.  
TLR5 is the innate immune receptor for flagellin [67] and mice knock-out (KO) for this receptor 
develop an altered GM due to deficits in the immune system. TLR5KO mice have an altered host-
microbe interactions, increased inflammation and metabolic syndrome [68]. It has been 
demonstrated that metabolic phenotype in these mice depends on GM alteration as TLR5KO mice 
raised in GF conditions do not develop the metabolic phenotype [69]. Bone phenotype is 
significantly different in TLR5KO mice as respect to WT, these animals have larger cross-sectional 
area and moment of inertia with a reduction in whole-bone strength. The effect of antibiotic 
treatment and disruption of the GM on bone tissue material properties was different between WT 
and TLR5KO mice, in particular TLR5KO mice display a greater reduction of the whole-bone 
femoral bending stiffness as respect to WT [64]. These differences may be due to several 
characteristics of TLR5KO mice: these mice are mildly obese and it is known that obesity 
influences bone mechanical competence [70]; moreover GM is altered in TLRKO mice that display 
low microbial diversity, that might, per se, influence bone phenotype; finally immune system is 
altered in these animals, these could affect GM-immune system-bone interaction.   
 In order to study the role of innate immunity in mediating the effect of GM on bone health Ohlsson 
and colleagues [66] evaluated the role of Myd88, NOD1 and NOD2. Myd88 is the main mediator of 
TLR activity on inflammatory response [71], however Myd88KO mice behave like WT mice when 
raised in GF environment and display a significant increase in cortical bone mass, this observation 
demonstrates that the effect of the GM on bone mass is independent of Myd88.  
NOD1 and NOD2 bind bacterial peptidoglycan and cooperate to inflammatory response after 
bacterial recognition in the cytoplasm activating the NFκB pathway. NOD1 detects diaminopimelic 
acid-type peptidoglycan that is mainly expressed by Gram-negative bacteria [72]. Nod2 detects all 
types of peptidoglycans found in Gram-positive and Gram-negative bacteria [73].GF mice with 
deletion of NOD1 or NOD2 do not have increased cortical thickness nor increased expression of 
TNFα and RANKL, thus the effect of GM on the production of this cytokines and, hence, on bone 
mass is dependent by these molecules. 
To investigate the role of GM in bone loss induced by sex steroid deficiency, this condition was 
induced pharmacologically in GF mice with the GnRH agonists leuprolide by Li and colleagues 
[74].These authors demonstrated that GM plays an important role in sex steroid deficiency induced 
osteoporosis: GF mice are protected against osteoporosis and the increase in bone turnover induced 
by sex steroid deprivation thanks to the lack of increase in TNF, RANKL, and IL-17. The authors 
also demonstrated that sex steroid depletion augments inflammation in the intestine by increasing 
gut permeability to bacterial antigens, namely by decreasing the expression of claudin 2, 3, and 15, 
and of Jam3, which are modulators of intestinal barrier integrity [75, 76].  
In humans scarce data support results obtained in mice, recently Wang and colleagues [77] in a very 
limited cohort suggest that GM component structure and diversity are altered in osteoporosis and 
osteopenia patients as compared with normal controls, however they do not correlate different GM 
components with inflammation and immune system, nor with bone turnover. 
Relationships between immune system, estrogen deficiency, bone loss and GM are summarized in 
Fig. 2. 
 
GM and bone health beyond immune system 
It has been suggested that GM composition and manipulation may affect bone health beyond 
immune system by influencing calcium absorption and the production of gut derived serotonin.  
A post-hoc analyses on the use of Lactobacillus reuteri demonstrated that the use of this probiotic 
in healthy subject increases the level of serum 25OH vitamin D, that influences calcium absorption 
and benefits bone health. The mechanism through which this probiotic influences vitamin D level is 
not clear, however the authors argued that this may be due to a modification in the gut environment 
that specifically favors vitamin D absorption or to indirect effect on increased hepatic 25-
hydroxylase activity or 7-dehydrocholesterol concentration due to reduced absorption of dietary and 
biliary cholesterol [78]. On the other hand the relation between GM and vitamin D may also be 
inverse as it has been proposed that decreased vitamin D intake is associated with different GM 
profile [79, 80]. 
Another possible mechanism through which GM benefits bone health is the increase in calcium 
absorption. It is well known that maintaining a positive calcium balance is important in achieving a 
good peak of bone mass that protects from the development of osteoporosis in older age [81, 82]. 
Dietary intake of fibers influences calcium absorption, after being fermented by GM, fibers improve 
calcium absorption by reduction of gut pH, thus reducing the formation of calcium phosphates and 
increasing the calcium absorption and by increasing the production of SCFAs as butyrate [83]. The 
effect of SCFAs may be more complex that the effect on gut pH and in fact it has been 
demonstrated that SCFAs increase calcium transport trough signaling pathway modulation [84].As 
previously said SCFAs influence bone health also trough immune system modulation, hence dietary 
fibers intake may be responsible for an healthier immune system and reduced inflammation, in fact 
there is a general consensus recognizing that an adequate dietary fiber intake is associated with 
lower risk of chronic diseases as cardiovascular diseases [85]. 
Another possible mechanism through which GM influences bone health is mediated by its effect on 
the production of gut serotonin (5HT). In the recent past a dual effect of serotonin in the regulation 
of bone mass has been described depending on the site of production of this molecule [86]. In this 
review we are interested in the role of gut derived 5HT (g5HT), that is influenced by GM, as a bone 
mass regulator. Enterochromaffin cells of the duodenum are responsible for the synthesis of g5HT 
that is partially modulated by GM as SCFAs increase the synthesis of g5HT [87, 88]. It has been 
shown that 5HT interacts with bone cells and, in particular, decreases osteoblast proliferation via 
activation of 5-HT1B receptors on pre-osteoblasts [89, 90].These observations suggest that 
regulation of g5HT by GM may be a potential therapeutic strategy to improve bone health, indeed, 
in animal models of ovariectomy induced bone loss, pharmacological inhibition of g5HT synthesis 
results in prevention of osteoporosis mediated by increased bone formation [91]. 
However data on the effect of 5HT on bone health are quite controversial, Cui and colleagues [92] 
showed that mice KO for 5HT receptor 1 have no bone phenotype and that inhibition of this 
receptor with LP923941, an enantiomer of LP533401 used in a previous study with opposite results 
[91], decreases circulating 5-HT, but has no effect on bone density. Different results obtained may 
be explained by different techniques used [93]. 
 
Relationships between GM and bone turnover beyond immune system are summarized in Fig. 3. 
 
GM manipulation and bone health 
GM composition may be manipulated in several ways as the use of broad spectrum antibiotics, 
change in dietary habits and, more easily, by the use of prebiotics and probiotics, change in GM 
composition may affect bone health. The majority of experimental data produced in mice 
demonstrated that modulation of GM by the use of probiotics is able to increase bone mass and to 
reduce sex steroid associated bone loss [74, 94-96]. Probiotics used were different in different 
studies, both a single strain or a mixture of strains, the most used were Lactobacilli spp. that were 
demonstrated to have the higher anti-inflammatory and bone protective effect. McCabe and 
colleagues suggested that short-term oral administration of the Lactobacillus reuteri enhanced bone 
density in male, but not in female mice [97], however in estrogen-deficient female mice the 
administration of this probiotic prevented bone loss [95]. In a further study the authors suggested 
that L. reuteri is active on bone health also in intact females providing the presence of an 
inflammatory status, the authors speculated that estrogen deficiency is comparable to a mild 
inflammatory status, thus explaining their previous findings on intact female [98]. 
Also some data on the use of yogurt that contains different probiotics, but is also a source of 
calcium and proteins that are fundamental for bone health, have been produced [99]. All these 
studies showed a protective effect of probiotic yogurt on bone health, moreover it has been 
demonstrated that dairy products consumption in early life led to a higher peak bone mass [100]. 
Also in adults older than 60 years consumption of dairy products was associated to increased bone 
density and lower risk of osteoporosis [101-104]. The use of probiotics has been proposed also as 
adjuvant treatment in focal bone loss as alveolar erosion in periodontitis, the ability of different 
Lactobacilli strains in reducing osteoclast number, alveolar erosions and tooth movement in rat and 
mice has been demonstrated [105-107]. In humans a recent meta-analysis concludes that current 
evidences suggest a possible use of probiotics as adjuvant therapy in gingivitis and periodontitis 
[108]. 
In a geriatric population the administration of Lactobacillus helveticus increases serum calcium 
[109]; in a prospective double-blind, placebo-controlled randomized clinical trial the administration 
of Lactobacillus casei Shirota in 417 elderly patients with a distal radius fracture accelerates the 
healing process [110]. Also in osteopenic women the administration of a multispecies probiotic (6 
different species) increases markers of bone formation, decreases TNF alpha level, but has no effect 
on bone density during a 6 months period [111]. 
Another method to influence GM is the administration of prebiotics, prebiotics are complex 
carbohydrate and fibers, that influence composition and/or activity of GM in a way that favors host 
health. To generate beneficial metabolic products GM need substrate availability, prebiotics 
partially provides these substrates, and can be used to modify the GM components and their 
metabolites. To be classified as prebiotic a substance should meet these criteria: be resistant to low 
gastric pH, hydrolysis by mammalian digestive enzymes, and not be absorbable by humans, be 
fermented by GM and stimulate the growth and activity of gastro intestinal tract [112]. Prebiotic 
supplementation in animal models favors the proliferation of Bifidobacteria and increases SCFAs 
production. As regards the effect of prebiotics on bone health some experimental studies showed 
that they improved calcium absorption and bone density in animal models [113, 114].In humans the 
supplementation with different probiotics as galacto-oligosaccharide and a mixture of short- and 
long-chain inulin-type fructans in adolescent girls improved calcium absorption and improved bone 
density [115, 116]. Recently the corn-derived non-digestible carbohydrate, soluble corn fiber (SCF), 
has been evaluated for its ability to increase calcium absorption and improve bone health in 
humans. In particular SCF administration enhances calcium absorption and its consumption is 
associated with a favorable change in GM, namely increased presence of Bacteroidetes and 
Firmicutes known to ferment starch and fiber [117, 118]. In the study by Whisner and colleagues 
[117] increase in calcium absorption was positively correlated with bone formation marker, also the 
changes observed in GM phyla proportion was associated with calcium absorption, Parabacteroides 
significantly increases with larger SCF doses and negatively correlated with calcium absorption. 
Firmicutes positively correlated with calcium absorption. The results of this elegant study suggests 
that the role of GM in calcium absorption is complex and due to different species. 
Prebiotic fiber may influence bone metabolism both by the change in composition of GM favoring 
microbes with higher anti-inflammatory potential and by increasing SCFAs production thus 
increasing the calcium absorption. It has also been suggested that prebiotics could have direct effect 
on immune system modulation and an anti-pathogen effects regardless to their effect on GM [119]. 
However, until now, in human studies on prebiotics only calcium absorption, markers of bone 
metabolism and bone density were investigated, whereas immune phenotype and inflammation 
were not. 
 
Conclusions 
GM is becoming one of the new players in the regulation of bone turnover by modulating immune 
system and controlling inflammation and also by influencing calcium absorption and vitamin D 
level.  
Dysbiosis may favor bone loss in aged people and after menopause ,manipulation of GM may 
become a future adjuvant treatment in preventing osteoporosis, osteopenia and other diseases 
characterized by focal bone loss as periodontitis.  
In the last years several data obtained in animal models strongly supported the role of GM in the 
control of bone turnover, less data have been published in humans, field in which confirmatory 
studies are needed. In particular large clinical trials are needed to clarify the efficacy of prebiotics 
and probiotics in favoring bone health during growth, aging and post-menopausal bone loss.  
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Figure legends 
Fig. 1 The cartoon summarizes how gut microbiota influences enteral barrier integrity and immune 
system through the production of several metabolites 
Abbreviations used: enteral cells (EC), goblet cells (GC), antigen presenting cells (APC); T 
regulatory cells (Treg); T helper-1 (Th1), Thelper-17 cells (Th17), Short Chain Fatty Acid (SCFAs) 
 
  
Fig. 2 The cartoon summarizes the complex relationships between immune system, estrogen 
deficiency-bone loss and gut microbiota: enteral barrier integrity, cytokine production, immune and 
bone cells are involved 
Abbreviations used: gut microbiota (GM) enteral cells (EC), antigen presenting cells (APC); T 
regulatory cells (Treg); T helper-1 (Th1), Thelper-17 cells (Th17), osteoblasts (OBs), osteoclasts 
(OCs) 
 
  
Fig. 3 The cartoon summarizes the link between gut microbiota and bone turnover beyond immune 
system  
Abbreviations used: gut microbiota (GM), enteral cells (EC), enterochromaffin cells (ECC), 
osteoblasts (OBs) 
 
 
 
 
 
 
 
 
 
 
